Bioelastomeric stent

• US 5,628,785 A
• Filed: 04/27/1995
• Issued: 05/13/1997
• Est. Priority Date: 03/19/1992
• Status: Expired due to Fees

• Current Assignee: Medtronic Incorporated (Medtronic Plc)
• Original Assignee: Medtronic Incorporated (Medtronic Plc)
• Inventors: Schwartz, Robert S., Wolff, Rodney G.
• Primary Examiner(s): Weiss, John G.
• Assistant Examiner(s): CUDDIHY, FRANCIS KEVIN
• Application Number:
  US08/430,028
• Time in Patent Office: 747 Days
• Field of Search: 623/1, 623/11, 623/12, 606/191-200, 606/151-158, 600/36, 604/8, 604/104
• US Class Current: 128/898
• CPC Class Codes: A61F 2/0077 Special surfaces of prostheses, e.g. for improving ingrowth A61F2/30767 takes precedence
• CPC Class Codes: A61F 2/82 Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents stent-grafts for tubular structures of the body other than blood vessels A61F2/04; stent-grafts for blood vessels A61F2/07; instruments specially adapted for placement or removal of stents or stent-grafts A61F2/95; for closing wounds, or holding wounds closed A61B17/04 - A61B17/115; dilators A61M29/00
• CPC Class Codes: A61F 2240/001 Designing or manufacturing processes
• CPC Class Codes: A61F 2250/0067 Means for introducing or releasing pharmaceutical products into the body
• CPC Class Codes: A61L 2300/252 Polypeptides, proteins, e.g. glycoproteins, lipoproteins, cytokines
• CPC Class Codes: A61L 2300/416 Anti-neoplastic or anti-proliferative or anti-restenosis or anti-angiogenic agents, e.g. paclitaxel, sirolimus
• CPC Class Codes: A61L 2300/42 Anti-thrombotic agents, anticoagulants, anti-platelet agents
• CPC Class Codes: A61L 2300/622 Microcapsules
• CPC Class Codes: A61L 31/041 Mixtures of macromolecular compounds
• CPC Class Codes: A61L 31/046 Fibrin; Fibrinogen
• CPC Class Codes: A61L 31/047 Other specific proteins or polypeptides not covered by A61L31/044 - A61L31/046
• CPC Class Codes: A61L 31/10 Macromolecular materials
• CPC Class Codes: A61L 31/128 containing other specific inorganic fillers not covered by A61L31/126 or A61L31/127
• CPC Class Codes: A61L 31/16 Biologically active materials, e.g. therapeutic substances A61L31/047 takes precedence
• CPC Class Codes: C08L 89/00 Compositions of proteins; Compositions of derivatives thereof foodstuff preparations A23J3/00
• CPC Class Codes: Y10S 623/901 Method of manufacturing prosthetic device

Abstract

An bioelastomeric intraluminal stent comprising fibrin and elastin is capable of providing a treatment of restenosis.

Claims

1. A method for making an intraluminal stent comprising the steps of:

(a) providing a stent comprising a plurality of spaced-apart elements;

(b) polymerizing a mixture of fibrin and elastin on the stent elements at an expanded stent diameter such that the polymer of fibrin and elastin extends between the spaced-apart stent elements; and

(c) radially compressing the stent and polymerized fibrin and elastin to a delivery diameter.

2. The method of claim 1 wherein the polymerizing step comprises applying to the stent successively (a) a solution of fibrinogen and elastin and (b) a solution of a fibrinogen-coagulating protein.

3. The method of claim 1 wherein the polymerizing step comprises (a) placing the stent in a mold and (b) introducing into the mold around the stent a solution of fibrinogen, elastin and a fibrinogen-coagulating protein.

4. The method of claim 1 also comprising the step of incubating the mixture of fibrin and elastin in a biological buffer solution.

5. The method of claim 1 also comprising the step of affixing the fibrin stent onto a distal end of a catheter.

6. A method for making an intraluminal stent comprising the steps of:

(a) providing an elastin stent comprising a plurality of spaced-apart elements;

(b) applying a fibrin film to the stent at an expanded stent diameter such that the fibrin extends between the spaced-apart stent elements; and

(c) radially compressing the stent and applied fibrin to a delivery diameter.

7. The method of claim 6 wherein the elastin stent is provided by forming an mixture of fibrin and elastin into an open-ended tubular shape.

8. The method of claim 6 also including the step of affixing the stent to a balloon on a balloon catheter.